## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.3% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($96.53)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. RVTY: Life sciences, software, and diagnostics show growth, with China stabilizing and margins set to improve**
- Source: TradingView | 20251202T180736 | Bullish | Relevance: 100%
- Revvity (RVTY) is experiencing increased activity in life sciences and instrumentation, with strong growth driven by software and AI initiatives. Immunodiagnostics and newborn screening are expanding, and the diagnostics sector in China is stabilizing after policy changes. The company anticipates positive margin and revenue outlooks for 2026.

**2. Jim Cramer Highlights That “Revvity’s the Cheapest in the Group”**
- Source: Insider Monkey | 20251204T120400 | Bullish | Relevance: 100%
- Jim Cramer highlighted Revvity, Inc. (NYSE: RVTY) as the "cheapest in the group" among life science companies, noting its recent better-than-expected financial results and raised full-year earnings forecast. The company, which originated from the breakup of PerkinElmer, is currently trading at around 21 times this year's earnings estimates. Revvity provides instruments, reagents, software, and sequencing services crucial for genetic testing, disease screening, and research applications.

**3. Revvity Inc. Stock Underperforms Monday When Compared To Competitors**
- Source: 富途牛牛 | 20251204T042511 | Somewhat-Bearish | Relevance: 100%
- Revvity Inc. (RVTY) stock underperformed on Monday compared to its competitors. The article briefly mentions Unity Software's (U.US) fourth-quarter earnings, stating that its revenue increased 35% year-over-year to $609 million, beating consensus estimates, despite reporting a quarterly loss of 66 cents per share.

**4. Korea Investment CORP Has $6.89 Million Position in Revvity Inc. $RVTY**
- Source: MarketBeat | 20251204T020944 | Bullish | Relevance: 99%
- Korea Investment CORP increased its stake in Revvity Inc. (NYSE:RVTY) by 61.7% in the second quarter, valuing its holding at $6.89 million. Other institutional investors also adjusted their positions, with institutional ownership now at 86.65%. Revvity announced a $1.00 billion share buyback program and a quarterly dividend of $0.07, while analysts maintain a "Moderate Buy" rating with an average target price of $114.75.

**5. Jim Cramer Recently Discussed These 9 Stocks**
- Source: Insider Monkey | 20251202T232300 | Bullish | Relevance: 98%
- Jim Cramer recently discussed nine stocks, highlighting Revvity, Inc. (NYSE:RVTY) due to its cheap valuation despite past disappointing results. Cramer noted Revvity's improved performance in October and raised full-year earnings forecast, positioning it as the most affordable in its group. The company provides essential instruments, reagents, software, and sequencing services for genetic testing and research.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.63 indicates undervaluation relative to growth. Forward P/E 19.3x stretched relative to 8% growth. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.2B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 7.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.63 |
| Forward P/E | 19.3 |
| Current P/E | 20.9 |
| YoY Growth | 7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 4.1% to -1.3% (-5.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.3pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.61), confirming momentum. OFD pattern: -DLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.26% (CS: 40) | Neutral |
| RSI_14 | 62.4 | Neutral |
| MACD Histogram | 0.61 | Bullish |
| vs SMA20 | 1.056x | Above |
| vs SMA50 | 1.088x | Above |
| vs SMA200 | 1.072x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $102.55
- **Stop Loss:** $96.53 (5.9% risk)
- **Target:** $108.57 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 83
- **Position Value:** $8,511.65
- **Portfolio %:** 8.51%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*